Literature DB >> 15946581

Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.

Brian J Byrne1, Jennifer Garst.   

Abstract

The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration, whereas cetuximab is being studied for use in NSCLC. Erlotinib has shown a survival advantage in patients with advanced NSCLC. Further studies have identified female sex, nonsmokers, Asian race, good performance status, and adenocarcinoma histology as predictors of patient response to these agents. A genetic mutation in EGFR has also been correlated with an increase in response.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15946581     DOI： 10.1007/s11912-005-0045-6

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


  28 in total

1.  Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.

Authors:  F M Sirotnak; M F Zakowski; V A Miller; H I Scher; M G Kris
Journal:  Clin Cancer Res       Date:  2000-12       Impact factor: 12.531

2.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Authors:  Roy S Herbst; Diane Prager; Robert Hermann; Lou Fehrenbacher; Bruce E Johnson; Alan Sandler; Mark G Kris; Hai T Tran; Pam Klein; Xin Li; David Ramies; David H Johnson; Vincent A Miller
Journal:  J Clin Oncol       Date:  2005-07-25       Impact factor: 44.544

3.  Cancer statistics, 2005.

Authors:  Ahmedin Jemal; Taylor Murray; Elizabeth Ward; Alicia Samuels; Ram C Tiwari; Asma Ghafoor; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2005 Jan-Feb       Impact factor: 508.702

4.  Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.

Authors:  F Ciardiello; R Caputo; R Bianco; V Damiano; G Pomatico; S De Placido; A R Bianco; G Tortora
Journal:  Clin Cancer Res       Date:  2000-05       Impact factor: 12.531

Review 5.  ErbB-targeted therapeutic approaches in human cancer.

Authors:  Carlos L Arteaga
Journal:  Exp Cell Res       Date:  2003-03-10       Impact factor: 3.905

6.  Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.

Authors:  Vincent A Miller; David H Johnson; Lee M Krug; Barbara Pizzo; Leslie Tyson; Wendy Perez; Peggy Krozely; Alan Sandler; David Carbone; Robert T Heelan; Mark G Kris; Robert Smith; Judith Ochs
Journal:  J Clin Oncol       Date:  2003-06-01       Impact factor: 44.544

7.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

Authors:  Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Journal:  JAMA       Date:  2003-10-22       Impact factor: 56.272

8.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

9.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

Authors:  Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Giorgio Scagliotti; Rafael Rosell; Vincent Miller; Ronald B Natale; Joan H Schiller; Joachim Von Pawel; Anna Pluzanska; Ulrich Gatzemeier; John Grous; Judith S Ochs; Steven D Averbuch; Michael K Wolf; Pamela Rennie; Abderrahim Fandi; David H Johnson
Journal:  J Clin Oncol       Date:  2004-03-01       Impact factor: 44.544

10.  Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

Authors:  Vincent A Miller; Mark G Kris; Neelam Shah; Jyoti Patel; Christopher Azzoli; Jorge Gomez; Lee M Krug; William Pao; Naiyer Rizvi; Barbara Pizzo; Leslie Tyson; Ennapadam Venkatraman; Leah Ben-Porat; Natalie Memoli; Maureen Zakowski; Valerie Rusch; Robert T Heelan
Journal:  J Clin Oncol       Date:  2004-03-15       Impact factor: 44.544
View more
  6 in total

1.  Development and validation of novel radiomics-based nomograms for the prediction of EGFR mutations and Ki-67 proliferation index in non-small cell lung cancer.

Authors:  Yinjun Dong; Zekun Jiang; Chaowei Li; Shuai Dong; Shengdong Zhang; Yunhong Lv; Fenghao Sun; Shuguang Liu
Journal:  Quant Imaging Med Surg       Date:  2022-05

2.  Rapid detection of epidermal growth factor receptor mutations with multiplex PCR and primer extension in lung cancer.

Authors:  Ching-Hsiung Lin; Kun-Tu Yeh; Ya-Sian Chang; Nicholas C Hsu; Jan-Gowth Chang
Journal:  J Biomed Sci       Date:  2010-05-12       Impact factor: 8.410

3.  Salivary protein factors are elevated in breast cancer patients.

Authors:  Mai N Brooks; Jianghua Wang; Yang Li; Rong Zhang; David Elashoff; David T Wong
Journal:  Mol Med Rep       Date:  2008 May-Jun       Impact factor: 2.952

4.  Epidemiology of lung cancer prognosis: quantity and quality of life.

Authors:  Ping Yang
Journal:  Methods Mol Biol       Date:  2009

5.  EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice.

Authors:  Alexei Shir; Manfred Ogris; Ernst Wagner; Alexander Levitzki
Journal:  PLoS Med       Date:  2005-12-06       Impact factor: 11.069

6.  M2 macrophages reduce the effect of gefitinib by activating AKT/mTOR in gefitinib-resistant cell lines HCC827/GR.

Authors:  Fengqi Xiao; Ni Liu; Xinchun Ma; Jing Qin; Yanguo Liu; Xiuwen Wang
Journal:  Thorac Cancer       Date:  2020-09-21       Impact factor: 3.500
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.